At a glance
- Originator National Institute on Aging
- Developer National Institute on Aging; TorreyPines Therapeutics Inc
- Class
- Mechanism of Action Acetylcholinesterase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Alzheimer's disease; Cognition disorders
Most Recent Events
- 08 Apr 2005 Discontinued - Preclinical for Alzheimer's disease in USA (unspecified route)
- 08 Apr 2005 Discontinued - Preclinical for Cognition disorders in USA (unspecified route)
- 10 Dec 2002 This compound is still in active development